-
Goldman Sachs: Odonate Therapeutics Has Potential, But There's Greater Upside Elsewhere
Tuesday, January 2, 2018 - 2:58pmRead More...Odonate Therapeutics Inc (NASDAQ: ODT) is a late-stage biopharmaceutical company focused on the treatment of HER2-/HR+ metastatic breast cancer. Most recently, the company began a Phase 3 study of its tesetaxel therapy Contessa. The Analyst Goldman Sachs' Dana Flanders initiated coverage...
-
More Bad News For Novavax: A Citi Downgrade
Tuesday, December 19, 2017 - 9:48amRead More...Novavax, Inc. (NASDAQ: NVAX), a small-cap clinical-stage vaccine company that focuses on therapies for both known and newly emerging diseases, has lost some support from a Wall Street analyst. The Analyst Citi's Joel Beatty downgraded Novavax's stock from Buy to Neutral. The Thesis...
-
Mallinkcrodt Is Betting On Ocera Despite Doubts Around Its Liver Disease Drug
Thursday, November 2, 2017 - 1:43pmRead More...Mallinckrodt PLC (NYSE: MNK), a generic specialty pharmaceutical company, said Thursday it has agreed to acquire Ocera Therapeutics Inc (NASDAQ: OCRX), a nano-cap clinical-stage biopharmaceutical company for $1.52 per share plus a contingent value right. Ocera's stock soared higher by 70...
-
-
Alder Biopharma Surged 60% Following Phase 2 Results
Monday, March 28, 2016 - 10:15amRead More...Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR), a clinical-stage biopharmaceutical company, surged higher by nearly 60 percent on Monday. Alder Biopharmaceuticals announced earlier in the morning positive top-line data from 2 clinical trials which studied its ALD403 product, an antibody...
